H e m a t o lo g y E d u c a t io n - European Hematology Association

leukemia with inv(16) and t(8;21): a Cancer and Leukemia
Group B Study. J Clin Oncol. 2006;24:3904-11.
5. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal
tandem duplication mutant level, number, size, and interaction
with NPM1 mutations in a large cohort of young adult patients
with acute myeloid leukemia. Blood. 2008;111:2776-84.
6. Caligiuri MA, Schichman SA, Strout MP, et al. Molecular
rearrangement of the ALL-1 gene in acute myeloid leukemia
without cytogenetic evidence of 11q23 chromosomal translocations.
Cancer Res. 1994;54:370-73.
7. Whitman SP, Hackanson B, Liyanarachchi S, et al. DNA
hypermethylation and epigenetic silencing of the tumor suppressor
gene, SLC5A8, in acute myeloid leukemia with the
MLL partial tandem duplication. Blood. 2008;112:2013-16.
8. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1
gene mutations are associated with a higher risk of recurrence
in young adults with acute myeloid leukemia: a study from
the Acute Leukemia French Association. Cancer. 2009;115:
3719-27.
9. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are
frequent in de novo AML with non complex karyotype and
confer an unfavourable prognosis. Blood. 2010.
10. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin
in acute myelogenous leukemia with a normal karyotype.
N Engl J Med. 2005;352:254-266.
11. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in
younger adults with acute myeloid leukemia and normal
cytogenetics: prognostic relevance and analysis of cooperating
mutations. J Clin Oncol. 2004;22:624-33.
12. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA
mutations in acute myeloid leukemia: most patients with
CEBPA mutations have biallelic mutations and show a distinct
immunophenotype of the leukemic cells. Clin Cancer
Res. 2005;11:1372-79.
13. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van
Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but
not single CEBPA mutations, define a subgroup of acute
myeloid leukemia with a distinctive gene expression profile
that is uniquely associated with a favorable outcome. Blood.
2009;113:3088-91.
14. Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is
an independent prognostic factor and allows refined risk
stratification in cytogenetically normal acute myeloid
leukemia: a comprehensive analysis of ERG, MN1, and BAALC
transcript levels using oligonucleotide microarrays. J Clin
Oncol. 2009;27:5031-38.
15. Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression
predicts outcome in younger adult patients with acute
myeloid leukemia and is associated with distinct cytogenetic
abnormalities. J Clin Oncol. 2010;28:2101-07.
16. Grimwade D, Hills RK, Moorman AV, et al. Refinement of
cytogenetic classification in acute myeloid leukemia: determination
of prognostic significance of rare recurring chromosomal
abnormalities among 5876 younger adult patients treated
in the United Kingdom Medical Research Council trials.
Blood. 2010;116:354-65.
17. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W,
Haferlach T. Mutations of the TP53 gene in acute myeloid
leukemia are strongly associated with a complex aberrant
karyotype. Leukemia. 2008;22:1539-41.
18. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal
karyotype in acute myeloid leukemia: a better indicator of
poor prognosis than a complex karyotype. J Clin Oncol.
2008;26:4791-97.
19. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR.
Prognostic impact of monosomal karyotype in young adult
and elderly acute myeloid leukemia: the Southwest Oncology
Group (SWOG) experience. Blood. 2010;116:2224-8.
20. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide
single nucleotide polymorphism analysis reveals frequent partial
uniparental disomy due to somatic recombination in
acute myeloid leukemias. Cancer Res. 2005;65:375-8.
21. Suela J, Alvarez S, Cifuentes F, et al. DNA profiling analysis of
100 consecutive de novo acute myeloid leukemia cases
reveals patterns of genomic instability that affect all cytogenetic
risk groups. Leukemia. 2007;21:1224-31.
22. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in
TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-301.
23. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute
myeloid leukemia. N Engl J Med. 2010;363:2424-33.
24. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations
found by sequencing an acute myeloid leukemia genome. N
Engl J Med. 2009;361:1058-66.
25. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene
London, United Kingdom, June 9-12, 2011
mutations identify novel molecular subsets within de novo
cytogenetically normal acute myeloid leukemia: a Cancer and
Leukemia Group B study. J Clin Oncol. 2010;28:2348-55.
26. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact
of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations
in acute myeloid leukemia: a study by the Acute
Leukemia French Association group. J Clin Oncol. 2010;28:
3717-23.
27. Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion
of ASXL1 and NPM1 mutations in a series of acute
myeloid leukemias. Leukemia. 2010;24:469-73.
28. Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and
AML M3 variant each have a distinct gene expression signature
but also share patterns different from other genetically
defined AML subtypes. Genes Chromosomes Cancer.
2005;43:113-27.
29. Ebert BL, Golub TR. Genomic approaches to hematologic
malignancies. Blood. 2004;104:923-32.
30. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful
gene-expression profiles in acute myeloid leukemia. N Engl J
Med. 2004;350:1617-28.
31. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression
profiling to identify prognostic subclasses in adult acute
myeloid leukemia. N Engl J Med. 2004;350:1605-16.
32. Figueroa ME, Reimers M, Thompson RF, et al. An integrative
genomic and epigenomic approach for the study of transcriptional
regulation. PLoS ONE. 2008;3:e1882.
33. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures
identify biologically distinct subtypes in acute myeloid
leukemia. Cancer Cell. 2010;17:13-27.
34. Muller-Tidow C, Klein HU, Hascher A, et al. Profiling of histone
H3 lysine 9 trimethylation levels predicts transcription
factor activity and survival in acute myeloid leukemia. Blood.
2010;116:3564-71.
35. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles
classify human cancers. Nature. 2005;435:834-8.
36. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles
in acute myeloid leukemia with common translocations. Proc
Natl Acad Sci U S A. 2008;105:15535-40.
37. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated
with cytogenetics and prognosis in acute myeloid
leukemia. Blood. 2008;111:3183-9.
38. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA
expression in cytogenetically normal acute myeloid leukemia.
N Engl J Med. 2008;358:1919-28.
39. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification
in acute myeloid leukemia. N Engl J Med. 2009;
361:1249-59.
40. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment
outcome in cytogenetically normal acute myeloid
leukemia. N Engl J Med. 2008;358:1909-18.
41. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.
Prognostic significance of CEBPA mutations in a large cohort
of younger adult patients with acute myeloid leukemia:
impact of double CEBPA mutations and the interaction with
FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739-47.
42. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human
acute myeloid leukaemia after transplantation into SCID
mice. Nature. 1994;367:645-8.
43. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation
of quiescent primitive leukemic progenitor cells from
patients with acute myeloid leukemia (AML). Blood. 2003;
101:3142-9.
44. Terpstra W, Ploemacher RE, Prins A, et al. Fluorouracil selectively
spares acute myeloid leukemia cells with long-term
growth abilities in immunodeficient mice and in culture.
Blood. 1996;88:1944-50.
45. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson
TM, Morrison SJ. Efficient tumour formation by single
human melanoma cells. Nature. 2008;456:593-8.
46. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor
growth need not be driven by rare cancer stem cells. Science.
2007;317:337.
47. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation
and progression of human acute leukemia in mice.
Science. 2007;316:600-4.
48. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation
of clonal architecture and propagating cells in leukaemia. Nature.
2011;469:356-61.
49. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid
leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML)
shows a distinct gene expression profile characterized by upregulation
of genes involved in stem-cell maintenance. Blood.
2005;106:899-902.
Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 33 |